Jennifer Ruddock | SVP of IR & Corporate Affairs |
Howard Robin | President & Chief Executive Officer |
Gil Labrucherie | SVP and Chief Financial Officer |
Steve Doberstein | SVP and Chief Scientific Officer |
Ivan Gergel | SVP of Drug Development and Chief Medical Officer |
Jonathan Zalevsky | SVP of Biology and Preclinical Development |
Ryan Tochihara | JP Morgan |
Chris Shibutani | Cowen and Company |
Bert Hazlett | BTIG |
Michael Higgins | Roth Capital Partners |
Andy Shay | William Blair |
David Steinberg | Jefferies |
Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Third Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call may be recorded. I would now like to introduce your host for today's conference, Ms.